title: Personalizing carbamazepine therapy.
abstract: The anticonvulsant carbamazepine has a high incidence of cutaneous adverse drug reactions. A recent prospective clinical trial in Taiwan has indicated that HLA-B*1502 screening will reduce the incidence of life-threatening adverse reactions to carbamazepine, while a genome-wide association study has identified the HLA-A*3101 allele as a genetic risk factor for the full spectrum of carbamazepine-induced cutaneous adverse drug reactions in a European population. These studies should aid future decision-making for personalized use of carbamazepine treatment.
authors.affiliation: Research Group for Pharmacogenomics, RIKEN Center for Genomic Medicine, Yokohama 230-0045, Japan. yusuke@ims.u-tokyo.ac.jp.
authors.forename: Taisei
authors.initials: T
authors.lastname: Mushiroda
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura